Bespoke Extracts Inc. Reports Q1 Revenue Growth to $263K, Net Loss Reduced to $260K

Reuters
07-08
Bespoke Extracts Inc. Reports Q1 Revenue Growth to $263K, Net Loss Reduced to $260K

Bespoke Extracts, Inc. (OTCQB: BSPK), a Colorado-based company in the regulated cannabis market, reported its financial results for the first quarter ended March 31, 2025. The company experienced a slight increase in sales, with revenues rising to $263,159, up 1.0% from $260,428 in Q1 2024. The growth was driven by strong direct sales of branded pre-rolled joints and expanded joint production services for licensed dispensaries in Colorado. Despite the sales increase, Bespoke Extracts reported a net loss of $260,521 for Q1 2025, an improvement from the net loss of $314,118 in Q1 2024. The company also highlighted a strategic rebranding of its product offerings under The Joint Company. Looking ahead, Bespoke Extracts provided an optimistic outlook for the second quarter of 2025. Based on preliminary sales data, the company projects revenues exceeding $385,000 for the quarter ending June 30, 2025, compared to $278,163 in Q2 2024. This forecasted growth is attributed to the continued demand for its new product lines, including FreshJoints, Doobskis, and Dutch Blunts, as well as expanded third-party processing services. Additionally, improvements in manufacturing processes are expected to support higher production volumes and consistent product quality.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bespoke Extracts Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-061778), on July 07, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10